University of Michigan Rogel Cancer Center: Multiple Myeloma trials
The registry lists 12 Multiple Myeloma studies with University of Michigan Rogel Cancer Center as lead sponsor. 0 are open to participants now and 8 have results posted.
Phase 1 3Phase 2 11No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based TherapyActive, not recruitingNCT04140162Phase 2Results posted
- Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple MyelomaCompletedNCT02331368Phase 2Results posted
- Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple MyelomaCompletedNCT01029054Phase 1/2Results posted
- Combination Study of Revlimid®, Velcade® Dexamethasone and Doxil® (RVDD)for Newly Diagnosed Multiple MyelomaCompletedNCT00724568Phase 1/2Results posted
- Stem Cell Transplantation To Treat High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning RegimenTerminatedNCT00615589Phase 2Results posted
- Study of Stem Cell Transplantation for Hematologic Malignancies Using Clofarabine and Busulfan RegimenCompletedNCT00556452Phase 1/2Results posted
- Study of Low-Intensity Conditioning for Allogeneic Stem Cell TransplantCompletedNCT00143845Phase 2Results posted
- Clinical Trial of Consolidation Treatment With Iodine I 131 Tositumomab for Multiple MyelomaCompletedNCT00135200Phase 2Results posted
- Low-Intensity Preparation and Allogeneic Transplant in Patients With Cancers of the BloodCompletedNCT00146055Phase 2
- Study of Low Intensity Conditioning and Immunotherapy for High-Risk Cancers of the BloodTerminatedNCT00143884Phase 2
- Study of Combination Therapy With VELCADE, Doxil, and Dexamethasone (VDd) in Multiple MyelomaCompletedNCT00135187Not applicable
- Velcade, Doxil, and Dexamethasone (VDd) as First Line Therapy for Multiple MyelomaCompletedNCT00116961Phase 2